Supernus Pharma (SUPN) Misses Q1 EPS by 1c

Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.08, $0.01 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $43 million versus the consensus estimate of $45.33 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance